Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI
Tóm tắt
18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) may improve cancer staging by combining sensitive cancer detection with high-contrast resolution and detail. We compared the diagnostic performance of 18F-FDG PET/MRI to 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for staging oesophageal/gastro-oesophageal cancer. Following ethical approval and informed consent, participants with newly diagnosed primary oesophageal/gastro-oesophageal cancer were enrolled. Exclusions included prior/concurrent malignancy. Following 324 ± 28 MBq 18F-FDG administration and 60-min uptake, PET/CT was performed, immediately followed by integrated PET/MRI from skull base to mid-thigh. PET/CT was interpreted by two dual-accredited nuclear medicine physicians and PET/MRI by a dual-accredited nuclear medicine physician/radiologist and cancer radiologist in consensus. Per-participant staging was compared with the tumour board consensus staging using the McNemar test, with statistical significance at 5%. Out of 26 participants, 22 (20 males; mean ± SD age 68.8 ± 8.7 years) completed 18F-FDG PET/CT and PET/MRI. Compared to the tumour board, the primary tumour was staged concordantly in 55% (12/22) with PET/MRI and 36% (8/22) with PET/CT; the nodal stage was concordant in 45% (10/22) with PET/MRI and 50% (11/22) with PET/CT. There was no statistical difference in PET/CT and PET/MRI staging performance (p > 0.05, for T and N staging). The staging of distant metastases was concordant with the tumour board in 95% (21/22) with both PET/MRI and PET/CT. Of participants with distant metastatic disease, PET/MRI detected additional metastases in 30% (3/10). In this preliminary study, compared to 18F-FDG PET/CT, 18F-FDG PET/MRI showed non-significant higher concordance with T-staging, but no difference with N or M-staging. Additional metastases detected by 18F-FDG PET/MRI may be of additive clinical value.
Tài liệu tham khảo
Belmouhand M et al (2019) Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction. Abdom Radiol 44(3):836–844. https://doi.org/10.1007/s00261-018-1841-4
Chan W et al (2011) Dual-time-point 18F-FDG-PET/CT imaging in the assessment of suspected malignancy. J Med Imag Radiat on 55(4):379–390. https://doi.org/10.1111/j.1754-9485.2011.02287.x
DaVee T, Ajani JA, Lee JH (2017) Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol 23(5):751–762. https://doi.org/10.3748/wjg.v23.i5.751
Enzinger PC, Mayer RJ (2003) Esophageal Cancer. N Engl J Med 349(23):2241–2252. https://doi.org/10.1056/nejmra035010
Kelly S et al (2001) A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 49(4):534. https://doi.org/10.1136/gut.49.4.534
Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A (2005) Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med Off Publ Soc Nucl Med 46(11):1819–1824
Lee G et al (2014) Clinical implication of PET/MR imaging in preoperative Esophageal Cancer Staging: comparison with PET/CT, endoscopic ultrasonography, and CT. J Nucl Med 55(8):1242–1247. https://doi.org/10.2967/jnumed.114.138974
Linder G, Korsavidou-Hult N, Bjerner T, Ahlström H, Hedberg J (2019) 18F-FDG-PET/MRI in preoperative staging of oesophageal and gastroesophageal junctional cancer. Clin Radiol 74(9):718–725. https://doi.org/10.1016/j.crad.2019.05.016
Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D, Committee EG (2016) Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl_5): v50–v57. doi:https://doi.org/10.1093/annonc/mdw329
Martin O et al (2019) PET/MRI versus PET/CT in whole-body staging: results from a unicenter observational study in 1003 subsequent examinations. J Nucl Med 61(8): jnumed.119.233940. doi:https://doi.org/10.2967/jnumed.119.233940
Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet 381(9864):400–412. https://doi.org/10.1016/s0140-6736(12)60643-6
Quint LE, Glazer GM, Orringer MB (1985) Esophageal imaging by MR and CT: study of normal anatomy and neoplasms. Radiology 156(3):727–731. https://doi.org/10.1148/radiology.156.3.4023234
Rice TW, Patil DT, Blackstone EH (2017) 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg 6(2):119–130. https://doi.org/10.21037/acs.2017.03.14
Riddell AM et al (2006) Potential of surface-coil MRI for staging of Esophageal Cancer. Am J Roentgenol 187(5):1280–1287. https://doi.org/10.2214/ajr.05.0559
Riddell AM, Allum WH, Thompson JN, Wotherspoon AC, Richardson C, Brown G (2007b) The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. Eur Radiol 17(2):391–399. https://doi.org/10.1007/s00330-006-0363-6
Riddell AM, Davies DC, Allum WH, Wotherspoon AC, Richardson C, Brown G (2007a) High-resolution MRI in evaluation of the surgical anatomy of the Esophagus and posterior mediastinum. Am J Roentgenol 188(1):W37–W43. https://doi.org/10.2214/ajr.05.1795
Ringheim A, de Neto GCC, Martins KM, Vitor T, da Cunha ML, Baroni RH (2018) Reproducibility of standardized uptake values of same-day randomized 68Ga-PSMA-11 PET/CT and PET/MR scans in recurrent prostate cancer patients. Ann Nucl Med 32(8): 523–531. doi: https://doi.org/10.1007/s12149-018-1275-7
Sjoquist KM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12(7):681–692. https://doi.org/10.1016/s1470-2045(11)70142-5
Takashima S et al (1991) Carcinoma of the esophagus: CT vs MR imaging in determining resectability. Am J Roentgenol 156(2):297–302. https://doi.org/10.2214/ajr.156.2.1898802
van Rossum PSN et al (2015) Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clin Radiol 70(1): 81–95. doi:https://doi.org/10.1016/j.crad.2014.07.017
van Hagen P et al. (2012) Preoperative chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med 366(22): 2074–2084. doi:https://doi.org/10.1056/nejmoa1112088
van Vliet EPM, Heijenbrok-Kal MH, Hunink MGM, Kuipers EJ, Siersema PD (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98(3): 547–557. doi:https://doi.org/10.1038/sj.bjc.6604200